From: The economic impact of chronic fatigue syndrome in Georgia: direct and indirect costs
All effects estimated relative to not-fatigued population, (Standard Errors in Parentheses) | ||||||
---|---|---|---|---|---|---|
 | Linear Ordinary Least Squares (OLS) for Untransformed Cost (y) | |||||
 | Total Expenditures ($2005) | Inpatient Hospital Expenditures ($2005) | Ambulatory Provider Visits ($2005) | Rx Medications ($2005) | OTC Medications ($2005) | Other Health Costs ($2005) |
Incremental Expenditures attributed to CFS | 716.47*** (237.12) | 22.50 (18.05) | 234.35*** (84.29) | 360.66** (171.28) | 111.99*** (36.98) | -13.03 (12.43) |
Incremental Expenditures Attributed to ISF | 526.88*** (189.66) | 8.74 (7.18) | 95.15** (38.31) | 379.09** (172.37) | 31.81 (26.80) | 12.09 (11.35) |
AIC | 7164.63 | 4544.74 | 5634.06 | 6906.44 | 5196.03 | 6361.90 |
BIC | 7167.03 | 4547.15 | 5636.46 | 6980.84 | 5198.44 | 6364.30 |
 | Generalized Linear Model for Untransformed Cost ((y+1)) a | |||||
Incremental Expenditures attributed to CFS | 946.73*** (323.22) | 16.61 (14.77) | 270.26** (106.17) | 783.05 (641.38) | 204.01* (111.16) | -1.83 (1.28) |
Incremental Expenditures Attributed to ISF | 481.50*** (111.62) | -0.88 (1.54) | 119.13*** (39.69) | 201.83** (102.30) | 46.83 (30.66) | 0.82 (1.37) |
AIC | 14.46 | 3.02 | 12.85 | 11.64 | 10.37 | 2.68 |
BIC | -2207.85 | -2754.06 | -2039.43 | -310.92 | -925.17 | -2767.13 |
 | Two-Part Model (TPM) for Untransformed Cost (y) b | |||||
Incremental Expenditures attributed to CFS | 950.18** (372.49) | -51.88 (145.88) | 270.08** (111.50) | 1024.33* (537.26) | 21.36 (51.29) | -480.13*** (46.27) |
Incremental Expenditures Attributed to ISF | 480.91*** (117.42) | -165.87 (138.01) | 118.28*** (38.35) | 447.29** (185.36) | 25.12 (44.77) | -322.10** (146.36) |
AIC | 289.52 | 144.74 | 459.89 | 559.91 | 564.81 | 83.92 |
BIC | -2126.02 | -1223.87 | -1550.25 | 279.4912 | -328.59 | -2643.75 |